



## Muscular Dystrophy -A Review

*Deepti Rajendra Jadhav, MS. Jadhav Pallavi*

Pratibhatai Pawar College of Pharmacy, Shirampur

**Corresponding Email:** [deeptijadhav103@gmail.com](mailto:deeptijadhav103@gmail.com)

### INTRODUCTION

The first historic account of MD used to be mentioned by way of Conte and Gioja in 1836. They described two brothers with innovative weak point beginning at age 10 years. These boys later developed generalized weak point and hypertrophy of a couple of muscle groups, which are now recognised to be attribute of the milder Becker MD. Muscular dystrophies are a team of muscle illnesses prompted by way of mutations in a person's genes. Over time, muscle weak spot decreases mobility, making day-to-day duties difficult. There are many types of muscular dystrophy, every affecting particular muscle groups, with symptoms and signs and symptoms acting at special ages, and various in severity. Muscular dystrophy can run in families, or a individual can be the first in their household to have a muscular dystrophy. There may additionally be quite a few exceptional genetic sorts inside every variety of muscular dystrophy, and human beings with the identical type of muscular dystrophy may additionally ride extraordinary symptoms.

Muscular dystrophies are rare, with little facts on how many human beings are affected. The Centers for Disease Control and Prevention (CDC) is working to estimate the quantity of human beings with every fundamental type of muscular dystrophy in the United States.

It used to be first described by means of the French neurologist Guillaume Benjamin Amand Duchenne in the 1860s, however till the 1980s, little was once acknowledged about the reason of any type of muscular dystrophy.

Muscular dystrophies (MD) are a genetically and clinically heterogeneous crew of uncommon neuromuscular ailments that motive modern weak point and breakdown of skeletal muscle tissues over time.[1] The issues vary as to which muscle tissues are specially affected, the diploma of weakness, how quickly they worsen, and when signs and symptoms begin.[1] Some sorts are additionally related with troubles in different organs.[2]

There is no therapy for any sickness from the muscular dystrophy group.[1] Several pills designed to tackle the root reason are below development, along with gene remedy (Microdystrophin), and antisense tablets (Ataluren, Eteplirsen etc).[2] Other medicines used consist of corticosteroids (Deflazacort), calcium channel blockers (Diltiazem) to sluggish skeletal and cardiac muscle degeneration, anticonvulsants to manipulate seizures and some muscle activity, and immunosuppressants (Vamorolone) to prolong injury to death muscle cells.[1] Physical therapy, braces, and corrective surgical operation might also assist with some symptoms[1] whilst assisted air flow might also be required in these with weak point of respiration muscles.[2]

Outcomes rely on the unique kind of disorder.[1] Many affected human beings will finally come to be unable to walk[2] and Duchenne muscular dystrophy in precise is related with shortened lifestyles expectancy.

Muscular dystrophy used to be first described in the 1830s with the aid of Charles Bell.[2]

### Symptoms:-

Muscle weak spot is the foremost symptom of muscular dystrophy. Depending on the type, the sickness impacts specific muscle groups and components of the body. Other symptoms of muscular dystrophy include:

- Enlarged calf muscles.
- Difficulty on foot or running.
- Unusual strolling gait (like waddling).
- Trouble swallowing.
- Heart problems, such as arrhythmia and coronary heart failure (cardiomyopathy).
- Learning disabilities.
- Stiff or free joints.
- Muscle pain.
- Curved backbone (scoliosis).
- Breathing problems.

### Causes:-

MD is triggered through mutations (alterations) in the genes accountable for healthful muscle shape and function. The mutations suggest that the cells that need to preserve your muscle mass can no longer fulfil this role, main to muscle weak spot and innovative disability.

Certain genes are concerned in making proteins that defend muscle fibers. Muscular dystrophy happens when one of these genes is defective. Each shape of muscular dystrophy is prompted through a genetic mutation unique to that kind of the disease. Most of these mutations are inherited.

---

## MUSCULAR DYSTROPHY DIAGNOSIS

A number of tests can help your doctor diagnose muscular dystrophy. Your doctor can perform:

### Blood testing-

High tiers of serum creatine kinase, serum aldolase, and myoglobin can also all sign the want for in addition checking out to verify or rule out muscular dystrophy.

### Genetic testing-

High tiers of creatine kinase and signs and symptoms of inadequate dystrophin may also point out a want for genetic testing. This kind of checking out appears for a giant mutation of the dystrophin (DMD) gene. If there's no giant mutation, the subsequent set of genetic assessments will seem to be for small mutations.

### Electromyography (EMG)-

EMG measures the muscle's electrical pastime the use of an electrode needle that enters your muscle. It can assist does to distinguish muscular dystrophy from a nerve disorder.

### Neurological bodily exam-

This examination guidelines out frightened device problems and identifies the country of muscle electricity and reflexes.

### Cardiac testing-

Cardiac trying out identifies coronary heart troubles that once in a while happen with muscular dystrophy. Tests encompass an echocardiogram to seem at the shape of the heart.

### Imaging tests-

MRI and ultrasound assist medical practitioner see the quantity of muscle inner the body.

### Exercise assessments-Exercise assessments

**Exercise assessments-**Exercise assessments appear at muscle strength, breathing, and how workout impacts the body at muscle strength, breathing, and how workout impacts the body.




---

## RISK FACTORS

Risk elements for muscular dystrophy:-

Muscular dystrophies are genetic conditions. A household records of muscular dystrophy is a hazard component for being a provider or creating muscular dystrophy. Because DMD and BMD are linked to the X chromosomes, kids assigned male are a whole lot greater probable to journey them.

However, even though youngsters assigned lady obtain an X chromosome from every guardian and ought to have enough dystrophin production, they can nonetheless ride signs of DMD or BMD, such as muscle cramps, weakness, and coronary heart issues.

### Complications of muscular dystrophy

Muscular dystrophy progresses a bit in another way for each person. Complications additionally differ relying on the kind of muscular dystrophy. Some of the extra frequent issues affect:

-Movement  
 -breathing  
 -the heart  
 -the spine

People with muscular dystrophy who turn out to be pregnant are additionally at a larger threat for sure problems at some point of gestation and lab.

---

## TREATMENTS

There's currently no cure for muscular dystrophy, but treatments can help manage your symptoms and slow the progression of the disease. Treatments depend on your symptoms and the kind of muscular dystrophy you have.

### Medications

The Food and Drug Administration (FDA) has approved new treatments for some people with DMD. Many of these treatments use a new process called "exon skipping," where the faulty segment (exon) of the dystrophin gene is patched over so the body can produce the protein.

#### These new treatments include:

##### Eteplirsen (Exondys 51)-

This weekly injection is for people with a specific mutation of the dystrophin gene that is amenable to exon 51 skipping. According to the FDA's 2016 approval notice, this applies to about 13 percent Trusted Source of people with DMD.

##### Golodirsen (Vyondys 53)-

This weekly injection is for people with a dystrophin gene difference amenable to exon 53 skipping. This applies to about 8 percent Trusted Source of people with DMD, according to the FDA's 2019 approval notice.

##### Viltolarsen (Viltepso)-

This is also a weekly injection for those with a dystrophin gene difference that's amenable to exon 53 skipping. The FDA approved viltolarsen (Viltepso) in 2020.

##### Casimersen (Amondys 45)-

This weekly injection is for those with a gene difference amenable to exon 45 skipping. This applies to about 8 percent Trusted Source of people with DMD, according to the FDA's 2021 approval notice.

##### Deflazacort (Emflaza)-

This is a corticosteroid available in tablet and oral suspension forms. It's approved for people ages 5 years and older with DMD.

### Muscle therapy-

Forms of muscle therapy have proven to be effective. These techniques involve working with a professional to improve physical function. Types of therapy include:

1. Physical therapy, including physical activity and stretching, to keep muscles strong and flexible
2. Respiratory therapy, to prevent or delay breathing problems
3. Speech therapy, to conserve muscle strength through specific techniques such as slower speech, pausing between breaths, and using special equipment
4. Occupational therapy, a process that focuses on daily activities, can help those with muscular dystrophy:
  - become more independent
  - gain access to community services
  - improve coping skills
  - improve social skills
  - Other treatments

#### Other treatment options include:

- corticosteroid drugs, which help strengthen muscles and slow muscle deterioration
- assisted ventilation if respiratory muscles are affected
- medication for cardiac problems
- surgery to treat cardiac problems
- surgery to help correct the shortening of muscles
- surgery to repair cataracts surgery to treat scoliosis

---

## AUTOSOMAL RECESSIVE INHERITED DISORDER

A person inherits a gene difference from both parents, on one of the 22 autosomal chromosomes. The parents are carriers of the gene but don't develop muscular dystrophy themselves.

Children have a 50 percent chance of inheriting one copy of the gene and becoming carriers, and a 25 percent chance of inheriting both copies. All sexes carry the risk equally.

### Sex-linked (X-linked) disorder



This inheritance is linked to the genes linked to the X chromosome. Parents might also raise two X chromosomes or an X and a Y chromosome. A toddler receives an X chromosome from one dad or mum and both an X or a Y chromosome from the other. If a toddler receives a gene difference on the X chromosome from the guardian with two X chromosomes, they'll emerge as carriers of the gene or boost muscular dystrophy. A infant with a erroneous X chromosome develops muscular dystrophy if they additionally inherit a Y chromosome (as is generally the case with adolescents assigned male at birth).

They're solely carriers if they inherit an X chromosome from the different guardian (as with teenagers assigned girl at birth). This different X chromosome offsets the impact of the X chromosome with the gene difference, as it can produce dystrophin.

### Spontaneous mutation

In this case, muscular dystrophy develops due to the fact of a spontaneous trade in genes. It takes place in human beings whose organic mother and father weren't carriers of the gene difference. Once the exchange occurs, the service can ignore it on to their children.

### Types of Muscular Dystrophy

1. Duchenne Muscular Dystrophy.
2. Becker Muscular Dystrophy.
3. Congenital Muscular Dystrophy.
4. Myotonic Muscular Dystrophy.
5. Limb-Girdle Muscular Dystrophy.
6. Facioscapulohumeral Muscular Dystrophy.
7. Emery–Dreifuss Muscular Dystrophy.
8. Distal Muscular Dystrophy.

### Stages of Muscular Dystrophy

**Stage 1:** Early Ambulatory. Stage 1: Early ambulatory stage.

**Stage 2:** Late Ambulatory. Stage 2: Late ambulatory stage.

**Stage 3:** Nonambulatory. Stage 3: Nonambulatory stage

## CONCLUSION

Duchenne muscular dystrophy (DMD) is a genetically X-linked disease of skeletal muscle characterized via innovative muscle atrophy. DMD is precipitated by means of more than a few mutations in the DMD gene and end result in a loss of the skeletal muscle protein dystrophin, which leads to a degradation of skeletal muscle. Animal fashions embody the majority of the literature surrounding workout and DMD. There is no remedy for DMD, however sub-maximal non-muscle unfavourable exercising may also enhance the satisfactory of lifestyles in men and women with DMD. Safe workouts for men and women with DMD include: flexibility workout (passive/active), reduced impact cardio workout (cycling or swimming), or isokinetic and uni-directional energy workout (concentric-only or eccentric-only). Due to the deadly nature of DMD, exercising prescription have to be tailor-made to meet the needs of every person to keep away from viable unfavourable results of exercise.

Muscular dystrophy is a team of ailments that motive modern weak spot and loss of muscle mass. In muscular dystrophy, bizarre genes (mutations) intervene with the manufacturing of proteins wanted to shape healthful muscle.

Muscular dystrophy is an inherited ailment that reasons modern muscle weak point (myopathy) and atrophy (loss of muscle mass) due to defects in one or greater genes required for regular muscle function. Some of the genes accountable for these stipulations have been recognized

---

**REFERENCE**

---

1. Suneja B, Suneja ES, Adlakha VK, Chandna P. A rare case report of neurodegenerative disease: Duchenne muscular dystrophy in two male siblings. *Int J Clin Pediatr Dent.* 2015;8:163–5. [PMC free article] [PubMed] [Google Scholar]
2. Yiu EM, Kornberg AJ. Duchenne muscular dystrophy. *Neurol India.* 2008;56:236–47. [PubMed] [Google Scholar]
3. Opas M, Michalak M. Duchenne muscular dystrophy. *Encyclopedia of Life Sciences.* London: Nature Publishing Group; 2001. [Google Scholar]
4. Bushby K, Finkel R, Birnkrant DJ, Case LE, Clemens PR, Cripe L, et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and pharmacological and psychosocial management. *Lancet Neurol.* 2010;9:77–93. [PubMed] [Google Scholar]
5. Hathout Y, Brody E, Clemens PR, Cripe L, DeLisle RK, Furlong P, et al. Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy. *Proc Natl Acad Sci U S A.* 2015;112:7153–8. [PMC free article] [PubMed] [Google Scholar]
6. Abbs S, Tuffery-Giraud S, Bakker E, Ferlini A, Sejersen T, Mueller CR. Best practice guidelines on molecular diagnostics in Duchenne/Becker muscular dystrophies. *Neuromuscul Disord.* 2010;20:422–7. [PubMed] [Google Scholar]
7. Flanigan KM. The muscular dystrophies. *Semin Neurol.* 2012;32:255–63. [PubMed] [Google Scholar]
8. Dey S, Senapati AK, Pandit A, Biswas A, Guin DS, Joardar A, et al. Genetic and clinical profile of patients of Duchenne muscular dystrophy: Experience from a tertiary care center in Eastern India. *Indian Pediatr.* 2015;52:481–4. [PubMed] [Google Scholar]
9. Sakthivel Murugan SM, Arthi C, Thilothammal N, Lakshmi BR. Carrier detection in Duchenne muscular dystrophy using molecular methods. *Indian J Med Res.* 2013;137:1102–10. [PMC free article] [PubMed] [Google Scholar]
10. Mercuri, E., Bonnemann, C. G. & Muntoni, F. Muscular dystrophies. *Lancet* 394, 2025–2038 (2019). Comprehensive overview of the clinical and genetic aspects of muscular dystrophies.
11. Aartsma-Rus, A., Van Deutekom, J. C. T., Fokkema, I. F., Van Ommen, G. J. B. & Den Dunnen, J. T. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. *Muscle Nerve* 34, 135–144 (2006).
12. Monaco, A. P., Bertelson, C. J., Liechti-Gallati, S., Moser, H. & Kunkel, L. M. An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. *Genomics* 2, 90–95 (1988).
13. García-Rodríguez, R. et al. Premature termination codons in the DMD gene cause reduced local mRNA synthesis. *Proc. Natl Acad. Sci. USA* 117, 16456–16464 (2020)
14. Ryder, S. et al. The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence review. *Orphanet J. Rare Dis.* 12, 79 (2017).
15. Bladen, C. L. et al. The TREAT-NMD Duchenne muscular dystrophy registries: conception, design, and utilization by industry and academia. *Hum. Mutat.* 34, 1449–1457 (2013)
16. Ferrier, P., Bamatter, F. & Klein, D. Muscular dystrophy (Duchenne) in a girl with Turner's syndrome. *J. Med. Genet.* 2, 38–46 (1965).
17. Magri, F. et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. *J. Neurol.* 258, 1610–1623 (2011).